Abstract
HER-2/neu amplification or overexpression can make cancer cells resistant to apoptosis and promotes their growth. p53 is crucial in regulating cell growth and apoptosis, and is often mutated or deleted in many types of tumour. Moreover, many tumours with a wild-type gene for p53 do not have normal p53 function, suggesting that some oncogenic signals suppress the function of p53. In this study, we show that HER-2/neu-mediated resistance to DNA-damaging agents requires the activation of Akt, which enhances MDM2-mediated ubiquitination and degradation of p53. Akt physically associates with MDM2 and phosphorylates it at Ser166 and Ser186. Phosphorylation of MDM2 enhances its nuclear localization and its interaction with p300, and inhibits its interaction with p19ARF, thus increasing p53 degradation. Our study indicates that blocking the Akt pathway mediated by HER-2/neu would increase the cytotoxic effect of DNA-damaging drugs in tumour cells with wild-type p53.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
Yu, D. & Hung, M.-C. in DNA Alterations in Cancer (ed. Ehrlich, M.) Ch. 21 (Eaton, Natick, Massachusetts, 2000).
Zhou, B. P. et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathways. J. Biol. Chem. 275, 8027–8031 (2000).
Zhou, B. P. et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biol. 3, 245–252 (2001).
Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10, 262–267 (1998).
Datta, S. R., Brunet, A. & Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 13, 2905–2927 (1999).
Peso, L. D., Gonzalez-Garcia, M., Page, C., Herrera, R. & Nunez, G. Interleukin-3-induced phosphorylation of bad through the protein kinase Akt. Science 278, 687–689 (1997).
Cardone, M. H. et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318–1321 (1998).
Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857–868 (1999).
Kops, G. J. P. L. et al. Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 398, 630–634 (1999).
Ozes, O. N. et al. NF-κB activation by tumor necrosis factor requires the Akt serine–threonine kinase. Nature 401, 82–85 (1999).
Sabbatini, P. & McCormick, F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J. Biol. Chem. 274, 24263–24269 (1999).
Woods, D. B. & Vousden, K. H. Regulation of p53 function. Exp. Cell Res. 264, 56–66 (2001).
Sherr, C. J. & Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10, 94–99 (2000).
Vousden, K. H. p53: death star. Cell 103, 691–694 (2000).
Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000).
Hupp, T. R., Lane, D. P. & Ball, K. L. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 352, 1–17 (2000).
Caspari, T. Checkpoints: how to activate p53. Curr. Biol. 10, R315–R317 (2000).
Momand, J., Wu, H.-H. & Dasgupta, G. MDM2—master regulator of the p53 tumor suppressor protein. Gene 242, 15–29 (2000).
Colman, M. S., Afshari, C. A. & Barrett, J. C. Regulation of p53 stability and activity in response to genotoxic stress. Mut. Res. 462, 179–188 (2000).
Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J. & Livingston, D. M. Binding and modulation of p53 by p300/CBP coactivators. Nature 387, 823–827 (1997).
Grossman, S. R. et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2, 405–415 (1998).
Pomerantz, J. et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and nuetralizes MDM2's inhibition of p53. Cell 92, 713–723 (1998).
Zhang, Y., Xiong, Y. & Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-Ink4a locus deletion impairs both Rb and p53 tumor suppressor pathways. Cell 92, 725–734 (1998).
Sherr, C. J. The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res. 60, 3689–3695 (2000).
Honda, R. & Yasuda, H. Association of p19ARF with MDM2 inhibits ubiquitin ligase activity of MDM2 for tumor suppressor p53. EMBO J. 18, 22–27 (1999).
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J. & Bar-Sagi, D. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol. 1, 20–26 (1999).
Zhang, Y. & Xiong, Y. Mutation in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3, 579–591 (1999).
Yu, D. & Hung, M.-C. Role of erbB2 in breast cancer chemosensitivity. BioEssays 22, 673–680 (2000).
Tsai, C. M. et al. Enhanced chemoresistance by elevation of p185 levels in HER-2/neu-transfected human lung cancer cells. J. Natl Cancer Inst. 87, 682–684 (1995).
Zhou, B.-B. S. & Elledge, S. J. The DNA damage response: putting checkings in perspective. Nature 408, 433–439 (2000).
Freedman, D. A. & Levine, A. J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18, 7288–7293 (1998).
Khosravi, R. et al. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl Acad. Sci. USA 96, 14973–14977 (1999).
Lianos, S., Clark, P. A., Rowe, J. & Peters, G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nature Cell Biol. 3, 445–452 (2001).
Mayo, L. D. & Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl Acad. Sci. USA 98, 11598–11603 (2001).
Acknowledgements
We thank G. Lozano for kindly providing p53−/− MEF and p53−/−, MDM2−/− MEF cells. This work was supported by grants CA 58880, CA 77858 and CA 78633, by a SPORE grant in ovarian cancer (CA 83639) (to M.-C.H.), and by the Nellie Connally Breast Cancer Research Fund at the M. D. Anderson Cancer Center (to M.-C.H.). B.P.Z. and Y.L. are recipients of postdoctoral fellowships from US Department of Defense Breast Cancer Research Training Grant DAMD17-99-1-9264 and US Department of Defense Breast Cancer Research Program (DAMD17-01-0300), respectively.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhou, B., Liao, Y., Xia, W. et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3, 973–982 (2001). https://doi.org/10.1038/ncb1101-973
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb1101-973
This article is cited by
-
FOXO transcription factors as mediators of stress adaptation
Nature Reviews Molecular Cell Biology (2024)
-
Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9
Nature Communications (2023)
-
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis
Nature Communications (2023)
-
Death-associated protein kinase 1 phosphorylates MDM2 and inhibits its protein stability and function
Archives of Pharmacal Research (2023)
-
Role of EGFR and FASN in breast cancer progression
Journal of Cell Communication and Signaling (2023)